Abstract
The tumor necrosis factor (TNF) and interferon (IFN) are proto- and anti-oncogene that encode for a family of transcription factors which is among the most activated signaling factors in human cancer. In a majority of cancers, the upregulation of TNF and IFN are related to the alternative mechanism pathways. Studies over the past few years have shown that the signaling of inflammatory factors can help tumor cells dysregulation their microenvironment and evade the host immune response system. In this review, we are discussing tumor evasion and its escaping mechanisms for tumor growth and proliferation. We are focusing on the evasion and escape mechanism of both inflammatory factors that have significantly participated in cancer development. We conclude that a deeper understanding of immune evasion and recognition in terms of the role of TNF and IFN could lead to a new therapeutic strategy for the treatment of cancer, and knowledge could be used in relevant clinical experiments involved.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abdollahi A, Folkman J (2010) Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Drug Resist Updat 13(1–2):16–28
Abou-Ghazal M, Yang DS, Qiao W, Reina-Ortiz C, Wei J, Kong L-Y, Fuller GN, Hiraoka N, Priebe W, Sawaya R (2008) The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin Cancer Res 14(24):8228–8235
Aggarwal BB (2003) Signaling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 3(9):745–756. https://doi.org/10.1038/nri1184
Alvarez JV, Mukherjee N, Chakravarti A, Robe P, Zhai G, Chakladar A, Loeffler J, Black P, Frank DA (2007) A STAT3 gene expression signature in gliomas is associated with a poor prognosis. Transl Oncogenomics 2:99
Anichini A, Molla A, Mortarini R, Tragni G, Bersani I, Di Nicola M, Gianni AM, Pilotti S, Dunbar R, Cerundolo V, Parmiani G (1999) An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions. J Exp Med 190(5):651–667. https://doi.org/10.1084/jem.190.5.651
Antoniou KM, Ferdoutsis E (2003) Reviews interferons and their application in the diseases of the lung*. Chest 123(1):209–216. https://doi.org/10.1378/chest.123.1.209
Bajic D, Chester K, Neri D (2020) An antibody-tumor necrosis factor fusion protein that synergizes with oxaliplatin for treatment of colorectal cancer. Mol Cancer Ther 19(12):2554–2563
Bake V, Roesler S, Eckhardt I, Belz K, Fulda S (2014) Synergistic interaction of Smac mimetic and IFNα to trigger apoptosis in acute myeloid leukemia cells. Cancer Lett 355(2):224–231. https://doi.org/10.1016/j.canlet.2014.08.040
Bates JP, Derakhshandeh R, Jones L, Webb TJ (2018) Mechanisms of immune evasion in breast cancer. BMC Cancer 18(1):556. https://doi.org/10.1186/s12885-018-4441-3
Beatty GL, Paterson Y (2001) Regulation of tumor growth by IFN-γ in cancer immunotherapy. Immunol Res 24:201–210
Bidwell BN, Slaney CY, Withana NP, Forster S, Cao Y, Loi S, Andrews D, Mikeska T, Mangan NE, Samarajiwa SA, de Weerd NA, Gould J, Argani P, Möller A, Smyth MJ, Anderson RL, Hertzog PJ, Parker BS (2012) Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med 18(8):1224–1231. https://doi.org/10.1038/nm.2830
Bodmer J-L, Schneider P, Tschopp J (2002) The molecular architecture of the TNF superfamily. Trends Biochem Sci 27(1):19–26. https://doi.org/10.1016/s0968-0004(01)01995-8
Booy S, Hofland L, Van Eijck C (2015) Potentials of interferon therapy in the treatment of pancreatic cancer. J Interferon Cytokine Res 35(5):327–339. https://doi.org/10.1089/jir.2014.0157
Broz ML, Binnewies M, Boldajipour B, Nelson AE, Pollack JL, Erle DJ, Barczak A, Rosenblum MD, Daud A, Barber DL (2014) Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 26(5):638–652
Buoncervello M, Romagnoli G, Buccarelli M, Fragale A, Toschi E, Parlato S, Lucchetti D, Macchia D, Spada M, Canini I, Sanchez M, Falchi M, Musella M, Biffoni M, Belardelli F, Capone I, Sgambato A, Vitiani LR, Gabriele L (2016) IFN-α potentiates the direct and immune-mediated antitumor effects of epigenetic drugs on both metastatic and stem cells of colorectal cancer. Oncotarget 7(18):26361–26373. https://doi.org/10.18632/oncotarget.8379
Burkart C, Arimoto K, Tang T, Cong X, Xiao N, Liu Y-C, Kotenko SV, Ellies LG, Zhang D-E (2013) Usp18 deficient mammary epithelial cells create an antitumour environment driven by hypersensitivity to IFN-λ and elevated secretion of Cxcl10. EMBO Mol Med 5(7):1035–1050. https://doi.org/10.1002/emmm.201201864
Cappuccini F, Pollock E, Stribbling S, Hill AVS, Redchenko I (2017) 5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy. Oncotarget 8(29):47474
Carpenter RL, Lo H-W (2014) STAT3 target genes relevant to human cancers. Cancers 6(2). https://doi.org/10.3390/cancers6020897
Castro F, Cardoso AP, Gonçalves RM, Serre K, Oliveira MJ (2018) Interferon-gamma at the crossroads of tumor immune surveillance or evasion. Front Immunol 9:1–19. https://doi.org/10.3389/fimmu.2018.00847
Chawla-Sarkar M, Lindner DJ, Liu Y-F, Williams BR, Sen GC, Silverman RH, Borden EC (2003) Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 8(3):237–249. https://doi.org/10.1023/a:1023668705040
Chen YR, Tan TH (2000) The c-Jun N-terminal kinase pathway and apoptotic signaling (review). Int J Oncol 16(4):651–662. https://doi.org/10.3892/ijo.16.4.651
Cheon H, Borden EC, Stark GR (2014) Interferons and their stimulated genes in the tumor microenvironment. Semin Oncol 41(2):156–173. https://doi.org/10.1053/j.seminoncol.2014.02.002
Chin YE, Kitagawa M, Su WC, You ZH, Iwamoto Y, Fu XY (1996) Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science 272(5262):719–722. https://doi.org/10.1126/science.272.5262.719
Chow KT, Gale M (2015) SnapShot: interferon signaling. Cell 163(7):1808–1808.e1. https://doi.org/10.1016/j.cell.2015.12.008
Costa-Pereira AP, Tininini S, Strobl B, Alonzi T, Schlaak JF, Is’harc H, Gesualdo I, Newman SJ, Kerr IM, Poli V (2002) Mutational switch of an IL-6 response to an interferon-gamma-like response. Proc Natl Acad Sci U S A 99(12):8043–8047. https://doi.org/10.1073/pnas.122236099
Coughlin CM, Salhany KE, Gee MS, LaTemple DC, Kotenko S, Ma X, Gri G, Wysocka M, Kim JE, Liu L, Liao F, Farber JM, Pestka S, Trinchieri G, Lee WM (1998) Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 9(1):25–34. https://doi.org/10.1016/s1074-7613(00)80585-3
Cruceriu D, Baldasici O, Balacescu O, Berindan-Neagoe I (2020) The dual role of tumor necrosis factor-alpha (TNF-α) in breast cancer: molecular insights and therapeutic approaches. Cell Oncol 43(1):1–18
Deng H, Zhang J, Yoon T, Song D, Li D, Lin A (2011) Phosphorylation of Bcl-associated death protein (Bad) by erythropoietin-activated c-Jun N-terminal protein kinase 1 contributes to survival of erythropoietin-dependent cells. Int J Biochem Cell Biol 43(3):409–415
Di Franco S, Turdo A, Todaro M, Stassi G (2017) Role of type I and II interferons in colorectal cancer and melanoma. Front Immunol 8. https://doi.org/10.3389/fimmu.2017.00878
Doherty MR, Cheon H, Junk DJ, Vinayak S, Varadan V, Telli ML (2017) Interferon-beta represses cancer stem cell properties in triple-negative breast cancer. Proc Natl Acad Sci U S A 114:1–6. https://doi.org/10.1073/pnas.1713728114
Dostert C, Grusdat M, Letellier E, Brenner D (2019) The TNF family of ligands and receptors: communication modules in the immune system and beyond. Physiol Rev 99(1):115–160
Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21(2):137–148
Eguchi H, Nagano H, Yamamoto H, Miyamoto A, Kondo M, Dono K, Nakamori S, Umeshita K, Sakon M, Monden M (2000) Augmentation of antitumor activity of 5-fluorouracil by interferon alpha is associated with up-regulation of p27Kip1 in human hepatocellular carcinoma cells. Clin Cancer Res 6(7):2881–2890
Ferrantini M, Capone I, Belardelli F (2007) Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie 89:884–893. https://doi.org/10.1016/j.biochi.2007.04.006
Fridman WH, Remark R, Goc J, Giraldo NA, Becht E, Hammond SA, Damotte D, Dieu-Nosjean M-C, Sautes-Fridman C (2014) The immune microenvironment: a major player in human cancers. Int Arch Allergy Immunol 164(1):13–26
Galdiero MR, Bonavita E, Barajon I, Garlanda C, Mantovani A, Jaillon S (2013) Tumor associated macrophages and neutrophils in cancer. Immunobiology 218(11):1402–1410
Ganapathi SK, Beggs AD, Hodgson SV, Kumar D (2014) Expression and DNA methylation of TNF, IFNG and FOXP3 in colorectal cancer and their prognostic significance. Br J Cancer 111(8):1581–1589. https://doi.org/10.1038/bjc.2014.477
Gandhi A, Guo T, Ghose R (2010) Role of c-Jun N-terminal kinase (JNK) in regulating tumor necrosis factor-alpha (TNF-alpha) mediated increase of acetaminophen (APAP) and chlorpromazine (CPZ) toxicity in murine hepatocytes. J Toxicol Sci 35(2):163–173. https://doi.org/10.2131/jts.35.163
Garancher A, Suzuki H, Haricharan S, Chau LQ, Masihi MB, Rusert JM, Norris PS, Carrette F, Romero MM, Morrissy SA, Skowron P, Cavalli FMG, Farooq H, Ramaswamy V, Jones SJM, Moore RA, Mungall AJ, Ma Y, Thiessen N, … Wechsler-Reya RJ (2020) Tumor necrosis factor overcomes immune evasion in p53-mutant medulloblastoma. Nat Neurosci 23(7):842–853. https://doi.org/10.1038/s41593-020-0628-4
Geva R, Voskoboynik M, Beebe AM, Gwo J, Dobrenkov K, Chartash E, Long GV (2018) First-in-human phase 1 study of MK-1248, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody, as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors. J Clin Oncol 36(15):3029
Gresser I, Belardelli F (2002) Endogenous type I interferons as a defense against tumors. Cytokine Growth Factor Rev 13(2):111–118. https://doi.org/10.1016/s1359-6101(01)00035-1
Gujam FJA, McMillan DC, Edwards J (2016) The relationship between total and phosphorylated STAT1 and STAT3 tumour cell expression, components of tumour microenvironment and survival in patients with invasive ductal breast cancer. Oncotarget 7(47):77607–77621. https://doi.org/10.18632/oncotarget.12730
Gutterman JU (1994) Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci U S A 91(4):1198–1205. https://doi.org/10.1073/pnas.91.4.1198
Hammouda MB, Ford AE, Liu Y, Zhang JY (2020) The JNK signaling pathway in inflammatory skin disorders and cancer. Cells 9(4):857. https://doi.org/10.3390/cells9040857
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674. https://doi.org/10.1016/j.cell.2011.02.013
Harashima S, Horiuchi T, Hatta N, Morita C, Higuchi M, Sawabe T, Tsukamoto H, Tahira T, Hayashi K, Fujita S, Niho Y (2001) Outside-to-inside signal through the membrane TNF-alpha induces E-selectin (CD62E) expression on activated human CD4+ T cells. J Immunol 166(1):130–136. https://doi.org/10.4049/jimmunol.166.1.130
Harlin H, Meng Y, Peterson AC, Zha Y, Tretiakova M, Slingluff C, McKee M, Gajewski TF (2009) Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 69(7):3077–3085. https://doi.org/10.1158/0008-5472.CAN-08-2281
Harvat B, Seth P, Jetten A (1997) The role of p27Kip1 in gamma interferon-mediated growth arrest of mammary epithelial cells and related defects in mammary carcinoma cells. Oncogene 14:2111–2122. https://doi.org/10.1038/sj.onc.1201055
Hasegawa K, Tagawa M, Takagi K, Tsukamoto H, Tomioka Y, Suzuki T, Nishioka Y, Ohrui T, Numasaki M (2016) Anti-tumor immunity elicited by direct intratumoral administration of a recombinant adenovirus expressing either IL-28A/IFN-λ2 or IL-29/IFN-λ1. Cancer Gene Ther 23(8):266–277. https://doi.org/10.1038/cgt.2016.29
Hastie C (2008) Interferon γ, a possible therapeutic approach for late-stage prostate cancer? Anticancer Res 28(5 B):2843–2849
Higuchi M, Nagasawa K, Horiuchi T, Oike M, Ito Y, Yasukawa M, Niho Y (1997) Membrane tumor necrosis factor-α (TNF-α) expressed on HTLV-I-infected T cells mediates a costimulatory signal for B cell activation – characterization of membrane TNF-α. Clin Immunol Immunopathol 82(2):133–140
Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-André V, Sigova AA, Hoke HA, Young RA (2013) Super-enhancers in the control of cell identity and disease. Cell 155(4):934–947. https://doi.org/10.1016/j.cell.2013.09.053
Ho HH, Ivashkiv LB (2006) Role of STAT3 in type I interferon responses: negative regulation of STAT1-dependent inflammatory gene activation. J Biol Chem 281(20):14111–14118
Hodge G, Barnawi J, Jurisevic C, Moffat D, Holmes M, Reynolds PN, Jersmann H, Hodge S (2014) Lung cancer is associated with decreased expression of perforin, granzyme B and interferon (IFN)-γ by infiltrating lung tissue T cells, natural killer (NK) T-like and NK cells. Clin Exp Immunol 178(1):79–85. https://doi.org/10.1111/cei.12392
Horiuchi T, Higuchi M, Harashima S, Sawabe T, Nishizaka H, Kojima T, Yoshizawa S, Niho Y, Nagasawa K (1998) Membrane TNF-α-mediated signal transduction in T cell-B cell interactions. In: Niho Y (ed) Molecular and genetic approaches to diseases – immunology, hematology, oncology, vol 1. Kyushu University Press, Fukuoka, p 11
Horiuchi T, Mitoma H, Harashima S, Tsukamoto H, Shimoda T (2010) Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents. Rheumatology 49(7):1215–1228. https://doi.org/10.1093/rheumatology/keq031
Horton B, Spranger S (2018) A tumor cell-intrinsic yin-yang determining immune evasion. Immunity 49(1):11–13
Hu S, Yuan J, Xu J, Li X, Zhang G, Ma Q, Zhang B, Hu T, Song G (2019) TNF-α and IFN-γ synergistically inhibit the repairing ability of mesenchymal stem cells on mice colitis and colon cancer. Am J Transl Res 11(9):6207–6220
Ivashkiv LB, Donlin LT (2014) Regulation of type I interferon responses. Nat Rev Immunol 14(1):36–49. https://doi.org/10.1038/nri3581
Jayachandran A, Dhungel B, Steel JC (2016) Epithelial-to-mesenchymal plasticity of cancer stem cells: therapeutic targets in hepatocellular carcinoma. J Hematol Oncol 9(1):1–12
Joyce JA, Fearon DT (2015) T cell exclusion, immune privilege, and the tumor microenvironment. Science 348(6230):74–80
Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119(6):1420–1428
Kosmidis C, Sapalidis K, Koletsa T, Kosmidou M, Efthimiadis C, Anthimidis G, Varsamis N, Michalopoulos N, Koulouris C, Atmatzidis S, Liavas L, Strati TM, Koimtzis G, Tsakalidis A, Mantalovas S, Zarampouka K, Florou M, Giannakidis DE, Georgakoudi E, … Kesisoglou I (2018) Interferon-γ and colorectal cancer: an up-to date. J Cancer 9(2):232–238. https://doi.org/10.7150/jca.22962
Kotenko SV (2011) IFN-λs. Curr Opin Immunol 23(5):583–590. https://doi.org/10.1016/j.coi.2011.07.007
Kotenko SV, Durbin JE (2017) Contribution of type III interferons to antiviral immunity: location, location, location. J Biol Chem 292(18):7295–7303. https://doi.org/10.1074/jbc.R117.777102
Kujawski LA, Talpaz M (2007) The role of interferon-alpha in the treatment of chronic myeloid leukemia. Cytokine Growth Factor Rev 18:459–471. https://doi.org/10.1016/j.cytogfr.2007.06.015
Kwon H, Lok AS (2011) Hepatitis B therapy. Nat Rev Gastroenterol Hepatol 8(5):275–284. https://doi.org/10.1038/nrgastro.2011.33
Lamb JA, Ventura J-J, Hess P, Flavell RA, Davis RJ (2003) JunD mediates survival signaling by the JNK signal transduction pathway. Mol Cell 11(6):1479–1489. https://doi.org/10.1016/s1097-2765(03)00203-x
Lasfar A, Lewis-Antes A, Smirnov SV, Anantha S, Abushahba W, Tian B, Reuhl K, Dickensheets H, Sheikh F, Donnelly RP, Raveche E, Kotenko SV (2006) Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma. Cancer Res 66(8):4468–4477. https://doi.org/10.1158/0008-5472.CAN-05-3653
Lasfar A, Gogas H, Zloza A, Kaufman HL, Kirkwood JM (2016) IFN-λ cancer immunotherapy: new kid on the block. Immunotherapy 8(8):877–888. https://doi.org/10.2217/imt-2015-0021
Lasfar A, Zloza A, Silk AW, Lee LY, Cohen-Solal KA (2018) Interferon lambda: 1–8. https://doi.org/10.1089/jir.2018.0046
Lee S-J, Lee E-J, Kim S-K, Jeong P, Cho Y-H, Yun SJ, Kim S, Kim G-Y, Choi YH, Cha E-J, Kim W-J, Moon S-K (2012) Identification of pro-inflammatory cytokines associated with muscle invasive bladder cancer; the roles of IL-5, IL-20, and IL-28A. PLoS One 7(9):e40267. https://doi.org/10.1371/journal.pone.0040267
Levy DE, Darnell JE (2002) Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3(9):651–662
Li N, Wang J, Zhang N, Zhuang M, Zong Z, Zou J, Li G, Wang X, Zhou H, Zhang L, Shi Y (2018) Cross-talk between TNF-α and IFN-γ signaling in induction of B7-H1 expression in hepatocellular carcinoma cells. Cancer Immunol Immunother 67(2):271–283. https://doi.org/10.1007/s00262-017-2086-8
Li J, He J, Wang Y, Shu Y, Zhou J (2019) SMC1 promotes proliferation and inhibits apoptosis through the NF-κB signaling pathway in colorectal cancer. Oncol Rep 42(4):1329–1342
Li Y, Song Y, Li P, Li M, Wang H, Xu T, Yu X, Yu Y, Tai Y, Chen P, Cai X, Wang X, Xiang L, Deng R, Zhang X, Gao L, Wang X (2020) Downregulation of RIG-I mediated by ITGB3/c-SRC/STAT3 signaling confers resistance to interferon-α-induced apoptosis in tumor-repopulating cells of melanoma. J Immunother Cancer 8:e000111. https://doi.org/10.1136/jitc-2019-000111
Lo H-W, Hsu S-C, Ali-Seyed M, Gunduz M, Xia W, Wei Y, Bartholomeusz G, Shih J-Y, Hung M-C (2005) Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell 7(6):575–589
Lo H-W, Hsu S-C, Xia W, Cao X, Shih J-Y, Wei Y, Abbruzzese JL, Hortobagyi GN, Hung M-C (2007) Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res 67(19):9066–9076
Lo H-W, Cao X, Zhu H, Ali-Osman F (2008) Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators. Clin Cancer Res 14(19):6042–6054
Lopez-Bujanda Z, Drake CG (2017) Myeloid-derived cells in prostate cancer progression: phenotype and prospective therapies. J Leukoc Biol 102(2):393–406
MacAndrew C, Steele T (1991) Gray’s behavioral inhibition system: a psychometric examination. Personal Individ Differ 12(2):157–171. https://doi.org/10.1016/0191-8869(91)90099-W
Maemura M, Iino Y, Horiguchi J, Takei H, Horii Y, Koibuchi Y, Yokoe T, Takeyoshi I, Ohwada S, Morishita Y (1999) Effects of interferon-alpha on cellular proliferation and adhesion of breast carcinoma cells. Oncol Rep 6(3):557–561
Mani SKK, Andrisani O (2019) Interferon signaling during hepatitis B virus (HBV) infection and HBV-associated hepatocellular carcinoma. Cytokine 124:90–95. https://doi.org/10.1016/j.cyto.2018.08.012
Martin JHJ, Symonds A (2002) Synergistic antitumour effect of a combination of toremifene and interferon-alpha on ZR-75-1 human breast cancer cells: dependence on interferon-alpha subtype. Oncol Rep 9(2):379–382
Martini M, Testi MG, Pasetto M, Picchio MC, Innamorati G, Mazzocco M, Ugel S, Cingarlini S, Bronte V, Zanovello P, Krampera M, Mosna F, Cestari T, Riviera AP, Brutti N, Barbieri O, Matera L, Tridente G, Colombatti M, Sartoris S (2010) IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer. Vaccine 28(20):3548–3557. https://doi.org/10.1016/j.vaccine.2010.03.007
Mathieu MG, Miles AK, Ahmad M, Buczek ME, Pockley AG, Rees RC, Regad T (2014) The helicase HAGE prevents interferon-α-induced PML expression in ABCB5+ malignant melanoma-initiating cells by promoting the expression of SOCS1. Cell Death Dis 5(2):e1061. https://doi.org/10.1038/cddis.2014.29
Meng Z, Wang X, Gan Y, Zhang Y, Zhou H, Van Ness C, Wu J, Lou G, Yu H, He C (2012) Deletion of IFNγ enhances hepatocarcinogenesis in FXR knockout mice. J Hepatol 57(5):1004–1012
Minn AJ, Wherry EJ (2016) Combination cancer therapies with immune checkpoint blockade: convergence on interferon signaling. Cell 165(2):272–275. https://doi.org/10.1016/j.cell.2016.03.031
Mittal D, Gubin MM, Schreiber RD, Smyth MJ (2014) New insights into cancer immunoediting and its three component phases – elimination, equilibrium and escape. Curr Opin Immunol 27:16–25
Montfort A, Colacios C, Levade T, Andrieu-Abadie N, Meyer N, Ségui B (2019) The TNF paradox in cancer progression and immunotherapy. Front Immunol 10:1818. https://doi.org/10.3389/fimmu.2019.01818
Muenst S, Läubli H, Soysal SD, Zippelius A, Tzankov A, Hoeller S (2016) The immune system and cancer evasion strategies: therapeutic concepts. J Intern Med 279(6):541–562. https://doi.org/10.1111/joim.12470
Nagano H (2010) Treatment of advanced hepatocellular carcinoma: intraarterial infusion chemotherapy combined with interferon. Oncology 78(Suppl 1):142–147. https://doi.org/10.1159/000315243
Negishi H, Taniguchi T, Yanai H (2018) The interferon (IFN) class of cytokines and the IFN regulatory factor (IRF) transcription factor family. Cold Spring Harb Perspect Biol 10(11):1–7. https://doi.org/10.1101/cshperspect.a028423
Ni L, Lu J (2018) Interferon gamma in cancer immunotherapy. Cancer Med 7(9):4509–4516. https://doi.org/10.1002/cam4.1700
Nicolini A, Carpi A, Rossi G (2005) An immunotherapy schedule in endocrine-dependent metastatic breast cancer: correlation between clinical course and immunologic parameters. J Immunother 28(3):276–279. https://doi.org/10.1097/01.cji.0000156827.67572.53
Nicolini A, Carpi A, Rossi G (2006) Cytokines in breast cancer. Cytokine Growth Factor Rev 17(5):325–337. https://doi.org/10.1016/j.cytogfr.2006.07.002
Nicolini A, Ferrari P, Diodati L, Carpi A (2018) Alterations of signaling pathways related to the immune system in breast cancer: new perspectives in patient management. Int J Mol Sci 19(9):2733. https://doi.org/10.3390/ijms19092733
Ningrum RA (2014) Human interferon alpha-2b: a therapeutic protein for cancer treatment. Scientifica 2014:1–9
Ouyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG (2011) Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol 29:71–109. https://doi.org/10.1146/annurev-immunol-031210-101312
Papaevangelou E, Smolarek D, Smith RA, Dasgupta P, Galustian C (2020) Targeting prostate cancer using intratumoral cytotopically modified interleukin-15 immunotherapy in a syngeneic murine model. Immunotargets Ther 9:115
Parker BS, Rautela J, Hertzog PJ (2016) Antitumour actions of interferons: implications for cancer therapy. Nat Rev Cancer 16(3):131–144. https://doi.org/10.1038/nrc.2016.14
Pestka S (2003) A dance between interferon-α/β and p53 demonstrates collaborations in tumor suppression and antiviral activities. Cancer Cell 4(2):85–87. https://doi.org/10.1016/S1535-6108(03)00193-4
Pfeffer LM (2011) The role of nuclear factor κB in the interferon response. J Interf Cytokine Res 31(7):553–559. https://doi.org/10.1089/jir.2011.0028
Platanias LC (2005) Mechanisms of type-I- and type-II-interferon-mediated signaling. Nat Rev Immunol 5(5):375–386. https://doi.org/10.1038/nri1604
Pol JG, Lekbaby B, Redelsperger F, Klamer S, Mandouri Y, Ahodantin J, Bieche I, Lefevre M, Souque P, Charneau P, Gadessaud N, Kremsdorf D, Soussan P (2015) Alternative splicing-regulated protein of hepatitis B virus hacks the TNF-α-stimulated signaling pathways and limits the extent of liver inflammation. FASEB J 29(5):1879–1889. https://doi.org/10.1096/fj.14-258715
Provance OK, Lewis-Wambi J (2019) Deciphering the role of interferon alpha signaling and microenvironment crosstalk in inflammatory breast cancer. Breast Cancer Res 1:1–10
Razaghi A, Owens L, Heimann K (2016) Review of the recombinant human interferon gamma as an immunotherapeutic: impacts of production platforms and glycosylation. J Biotechnol 240:48–60
Ruan J, Qi Z, Shen L, Jiang Y, Xu Y, Lan L, Luo L, Yin Z (2015) Crosstalk between JNK and NF-κB signaling pathways via HSP27 phosphorylation in HepG2 cells. Biochem Biophys Res Commun 456(1):122–128. https://doi.org/10.1016/j.bbrc.2014.11.045
Savage PA, Leventhal DS, Malchow S (2014) Shaping the repertoire of tumor-infiltrating effector and regulatory T cells. Immunol Rev 259(1):245–258
Schoenhals JE, Cushman TR, Barsoumian HB, Li A, Cadena AP, Niknam S, Younes AI, Caetano MS, Cortez MA, Welsh JW (2018) Anti-glucocorticoid-induced tumor necrosis factor-related protein (GITR) therapy overcomes radiation-induced Treg immunosuppression and drives abscopal effects. Front Immunol 9:2170. https://doi.org/10.3389/fimmu.2018.02170
Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331(6024):1565–1570
Schürch C, Riether C, Amrein MA, Ochsenbein AF (2013) Cytotoxic T cells induce proliferation of chronic myeloid leukemia stem cells by secreting interferon-γ. J Exp Med 210(3):605–621. https://doi.org/10.1084/jem.20121229
Shim S-H, Sung M-W, Park S-W, Heo DS (2009) Absence of STAT1 disturbs the anticancer effect induced by STAT3 inhibition in head and neck carcinoma cell lines. Int J Mol Med 23(6):805–810
Shin G-C, Kang HS, Lee AR, Kim K-H (2016) Hepatitis B virus-triggered autophagy targets TNFRSF10B/death receptor 5 for degradation to limit TNFSF10/TRAIL response. Autophagy 12(12):2451–2466. https://doi.org/10.1080/15548627.2016.1239002
Shrestha R, Bridle KR, Crawford DHG, Jayachandran A (2020) TNF-α-mediated epithelial-to-mesenchymal transition regulates expression of immune checkpoint molecules in hepatocellular carcinoma. Mol Med Rep 21(4):1849–1860. https://doi.org/10.3892/mmr.2020.10991
Slaney CY, Möller A, Hertzog PJ, Parker BS (2013) The role of type I interferons in immunoregulation of breast cancer metastasis to the bone. Oncoimmunology 2(1):1–3. https://doi.org/10.4161/onci.22339
Speiser DE, Baumgaertner P, Barbey C, Rubio-Godoy V, Moulin A, Corthesy P, Devevre E, Dietrich P-Y, Rimoldi D, Liénard D, Cerottini J-C, Romero P, Rufer N (2006) A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: spontaneous priming and efficient boosting by vaccination. J Immunol 177(2):1338–1348. https://doi.org/10.4049/jimmunol.177.2.1338
Stark GR, Darnell JE Jr (2012) The JAK-STAT pathway at twenty. Immunity 36(4):503–514
Sukumar S, Wilson DC, Yu Y, Wong J, Naravula S, Ermakov G, Riener R, Bhagwat B, Necheva AS, Grein J (2017) Characterization of MK-4166, a clinical agonistic antibody that targets human GITR and inhibits the generation and suppressive effects of T regulatory cells. Cancer Res 77(16):4378–4388
Svensson C, Part K, Künnis-Beres K, Kaldmäe M, Fernaeus SZ, Land T (2011) Pro-survival effects of JNK and p38 MAPK pathways in LPS-induced activation of BV-2 cells. Biochem Biophys Res Commun 406(3):488–492. https://doi.org/10.1016/j.bbrc.2011.02.083
Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, Sasaki S, Imai K, Shibue T, Honda K, Taniguchi T (2003) Integration of interferon-α/β signaling to p53 responses in tumour suppression and antiviral defence. Nature 424(6948):516–523. https://doi.org/10.1038/nature01850
Thapa RJ, Basagoudanavar SH, Nogusa S, Irrinki K, Mallilankaraman K, Slifker MJ, Beg AA, Madesh M, Balachandran S (2011) NF-kappaB protects cells from gamma interferon-induced RIP1-dependent necroptosis. Mol Cell Biol 31(14):2934–2946. https://doi.org/10.1128/MCB.05445-11
Thomas DA, Massagué J (2005) TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8(5):369–380. https://doi.org/10.1016/j.ccr.2005.10.012
Tsai SY, Hsieh TC, Ardelt B, Darzynkiewicz Z, Wu JM (2002) Combined effects of onconase and IFN-beta on proliferation, macromolecular syntheses and expression of STAT-1 in JCA-1 cancer cells. Int J Oncol 20(5):891–896
Tucci M, Stucci S, Passarelli A, Giudice G, Dammacco F, Silvestris F (2014) The immune escape in melanoma: role of the impaired dendritic cell function. Expert Rev Clin Immunol 10(10):1395–1404
Uzé G, Monneron D (2007) IL-28 and IL-29: newcomers to the interferon family. Biochimie 89(6–7):729–734. https://doi.org/10.1016/j.biochi.2007.01.008
Van Winkle JA, Constant DA, Li L, Nice TJ (2020) Selective interferon responses of intestinal epithelial cells minimize tumor necrosis factor alpha cytotoxicity. J Virol 94(21). https://doi.org/10.1128/JVI.00603-20
Vanamee ÉS, Faustman DL (2018) Structural principles of tumor necrosis factor superfamily signaling. Sci Signal 11(511). https://doi.org/10.1126/scisignal.aao4910
Vitkin N, Nersesian S, Siemens DR, Koti M (2019) The tumor immune contexture of prostate cancer. Front Immunol 10:1–10. https://doi.org/10.3389/fimmu.2019.00603
Wang X, Schoenhals JE, Li A, Valdecanas DR, Ye H, Zang F, Tang C, Tang M, Liu C-G, Liu X (2017) Suppression of type I IFN signaling in tumors mediates resistance to anti-PD-1 treatment that can be overcome by radiotherapy. Cancer Res 77(4):839–850
Wang D, Zuo Q, He Q, Li B (2021) Targeted immunotherapies in gastrointestinal cancer: from molecular mechanisms to implications. Front Immunol 12:1–15. https://doi.org/10.3389/fimmu.2021.705999
Woo S-R, Corrales L, Gajewski TF (2015) Innate immune recognition of cancer. Annu Rev Immunol 33:445–474. https://doi.org/10.1146/annurev-immunol-032414-112043
Wu Q, Wu W, Fu B, Shi L, Wang X, Kuca K (2019) JNK signaling in cancer cell survival. Med Res Rev 39(6):2082–2104. https://doi.org/10.1002/med.21574
Xiong A, Yang Z, Shen Y, Zhou J, Shen Q (2014) Transcription factor STAT3 as a novel molecular target for cancer prevention. Cancers 6(2):926–957
Zaidi MR (2019) The interferon-gamma paradox in cancer. J Interferon Cytokine Res 39(1):30–38. https://doi.org/10.1089/jir.2018.0087
Zaidi MR, Merlino G (2011) The two faces of interferon-g in cancer. Clin Cancer Res 17(19):6118–6125. https://doi.org/10.1158/1078-0432.CCR-11-0482
Zhang W, Shi X, Chen R, Zhu Y, Peng S, Chang Y, Nian X, Fang Z, Li Y, Cao Z (2020) Novel long non-coding RNA lncAMPC promotes metastasis and immunosuppression in prostate cancer by stimulating LIF/LIFR expression. Mol Ther 28(11):2473–2487
Zhang X, Wang S, Zhu Y, Zhang M, Zhao Y, Yan Z, Wang Q, Li X (2021) Double-edged effects of interferons on the regulation of cancer-immunity cycle. Oncoimmunology 10(1). https://doi.org/10.1080/2162402X.2021.1929005
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer Nature Switzerland AG
About this entry
Cite this entry
Seth, R., Kahar, N., Adile, S. (2022). Tumor Evasion of the Immune System: Role of Interferon and Tumor Necrosis Factor in Cancer. In: Rezaei, N. (eds) Handbook of Cancer and Immunology. Springer, Cham. https://doi.org/10.1007/978-3-030-80962-1_24-1
Download citation
DOI: https://doi.org/10.1007/978-3-030-80962-1_24-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-80962-1
Online ISBN: 978-3-030-80962-1
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences